Observational Study to Investigate the Long-term Effects of MIRCERA in Clinical Routine
This study has been completed.
Information provided by (Responsible Party):
First received: March 3, 2011
Last updated: March 9, 2015
Last verified: March 2015
This observational study will assess the effect of long-term treatment with Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients with renal anemia. Data will be collected from each patient for at least 24 months.
||Observational Model: Cohort
Time Perspective: Prospective
||Non-interventional Study to Investigate the Long Term Effects of MIRCERA in Clinical Routine
Primary Outcome Measures:
- Haemoglobin levels in relation to dosage used [ Time Frame: >/= 24 months ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||April 2014 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Chronic kidney disease patients treated with Mircera for renal anemia
- Adult patients, >/= 18 years of age
- Patients with chronic kidney disease (CKD), stages IV and V
- Treatment with Mircera according to label
- Pregnant or breastfeeding women
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01309269
|Lüdenscheid, Germany, 58515 |
No publications provided
ClinicalTrials.gov processed this record on March 26, 2015
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 3, 2011
||March 9, 2015
||Germany: Bundesinstitut für Arzneimittel und Medizinprodukte